To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing phase 3 clinical trials
Sorry I had to leave before you woke up. You’re right, it isn’t fair. Please empty the dishwasher today. And brush your teeth. Remember to feed the dog. He will die if no one remembers to do this.
The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor.
As of December 4, 2020, cases of novel coronavirus disease 2019 (COVID-19) have topped 14.3 million in the US with nearly 300 000 associated deaths. While mitigation measures such as social distancing, use of face coverings, and avoidance of crowds can help keep case counts in check, a safe and effective COVID-19 vaccine will be essential to ending the pandemic.
Certain antibodies and memory cells likely last more than 8 months after someone has contracted the coronavirus, especially if they have a strong immune response to COVID-19, according to a new study published Wednesday in Science.
